Quoin insider buys 20,490 ADSs at $4.88 each
After the ADS purchase, insider Carter directly owns 37,709 ADSs, while the warrants are immediately exercisable under a beneficial ownership cap.
Rhea-AI Filing Summary
Quoin Pharmaceuticals, Ltd. (QNRX) director and Chief Operating Officer Denise P. Carter reported net purchases on August 31, 2026. She purchased 20,490 ADSs at $4.88 per ADS in a private placement and acquired 10,245 ordinary warrants with a $6.10 exercise price, giving the right to buy 10,245 ADSs. Each ADS represents 35 ordinary shares. The warrants are immediately exercisable, subject to a beneficial ownership cap, and will expire on the earlier of five years from issuance or 30 days after Quoin publicly announces that the primary endpoint has been met in clinical trial CL-QRX003-004 for Netherton Syndrome. Following the ADS purchase, Carter directly owns 37,709 ADSs.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 30,735 shares
Net Buy
2 txns
Insider
Carter Denise P.
Role
Chief Operating Officer
Bought
30,735 shs
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Ordinary Warrants (Right to Buy) F2, F3, F4, F1 | 10,245 | -- | -- |
| Purchase | ADSs F1, F2 | 20,490 | $4.88 | $100K |
Holdings After Transaction:
Ordinary Warrants (Right to Buy) — 10,245 contracts (Direct);
ADSs — 37,709 shares (Direct)
Footnotes (4)
- F1. Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
- F2. Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.
- F3. The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.
- F4. The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.
Key Figures
ADSs purchased: 20,490 ADSs
ADS purchase price: $4.88 per ADS
Ordinary warrants acquired: 10,245 warrants
+5 more
8 metrics
ADSs purchased
20,490 ADSs
Purchased on August 31, 2026 at $4.88 per ADS in a private placement
ADS purchase price
$4.88 per ADS
Combined purchase price for ADSs and accompanying warrants in private placement
Ordinary warrants acquired
10,245 warrants
Ordinary Warrants (Right to Buy) acquired with 50% warrant coverage
Warrant exercise price
$6.10 per ADS
Conversion or exercise price for the ordinary warrants acquired on August 31, 2026
ADS holdings after transaction
37,709 ADSs
Direct ownership reported after the August 31, 2026 ADS purchase
ADS to ordinary share ratio
1 ADS : 35 ordinary shares
Each ADS represents thirty-five ordinary shares of Quoin Pharmaceuticals
Total shares bought (ADSs and underlying warrants)
30,735 ADS-equivalent instruments
20,490 ADSs plus 10,245 ADS-underlying warrants purchased on August 31, 2026
Warrant maximum term
5 years
Warrants expire five years from issuance unless earlier terminated by trial endpoint announcement
Key Terms
American Depositary Shares, beneficial ownership cap, primary endpoint, clinical trial CL-QRX003-004, +1 more
5 terms
beneficial ownership cap financial
"The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap."
A beneficial ownership cap is a rule that limits how much of a company a single investor or related group can effectively control, even if legal ownership could be higher. Think of it as a speed limit for ownership that prevents any one party from accumulating a controlling stake; it matters to investors because it affects takeover risk, voting power, dilution, and potential returns by shaping who can influence corporate decisions.
primary endpoint medical
"30 days after the Issuer's public announcement that the primary endpoint has been met"
The primary endpoint is the single main result a clinical study is designed to measure to decide if a treatment works, like the finish line in a race that tells you who won. Investors care because meeting or missing this goal drives regulatory decisions, future sales expectations and stock value — it turns trial data into a clear yes-or-no signal about a drug’s commercial prospects.
clinical trial CL-QRX003-004 medical
"the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome."
private placement financial
"Purchased in Issuer's private placement of ADSs with 50% warrant coverage."
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
FAQ
What did Quoin Pharmaceuticals (QNRX) executive Denise P. Carter buy on August 31, 2026?
She purchased 20,490 ADSs of Quoin Pharmaceuticals at $4.88 per ADS in a private placement and acquired 10,245 ordinary warrants with a $6.10 exercise price, each warrant relating to one ADS.
How many QNRX ADSs does Denise P. Carter hold after these transactions?
After the August 31, 2026 transaction, Denise P. Carter directly holds 37,709 ADSs of Quoin Pharmaceuticals. This figure reflects her reported position following the purchase of 20,490 ADSs in the private placement.
What are the key terms of the Quoin Pharmaceuticals warrants purchased by Denise P. Carter?
She acquired 10,245 ordinary warrants with a $6.10 exercise price per underlying ADS. The warrants are immediately exercisable, subject to a beneficial ownership cap, and expire the earlier of five years from issuance or 30 days after a specified clinical trial endpoint announcement.
Was the QNRX insider purchase made under a Rule 10b5-1 trading plan?
The filing indicates the Rule 10b5-1 checkbox is not affirmed for these transactions, and there is no footnote stating that the purchases were made pursuant to a Rule 10b5-1 trading plan.
What triggers earlier expiration of the Quoin Pharmaceuticals warrants?
The warrants expire on the earlier of five years from issuance or 30 days after Quoin’s public announcement that the primary endpoint has been met in clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.
AI-generated analysis. How Rhea-AI works. Not financial advice.
